Cost avoidance from health system specialty pharmacist interventions in patients with multiple sclerosis

• DOI: 10.18553/jmcp.2024.30.4.336
• Publication Date: 2024-03-31T22:09:07Z
• Authors: Darina Georgieva; Brandon Markley; Josh DeClercq; Leena Choi; Autumn D. Zuckerman
• Keywords: Specialty; Medication therapy management; Natalizumab

Specialty pharmacists monitor patients taking multiple sclerosis (MS) disease-modifying therapies (DMTs) to evaluate response therapy and intervene on adverse effects. These interventions have the potential avoid health care costs by discontinuing inappropriate avoiding downstream utilization.